Glaucoma Therapeutics Market Sales to Reach US$ 10 Billion by 2031: Fact.MR

Rockville, United States, 2023-July-25 — /EPR Network/ —

As per  Fact.MR, a market research and competitive intelligence provider, from 2016 to 2020, the global market for glaucoma therapeutics has grown at a CAGR of almost 2.8%. Recent advancements in therapeutic interventions, such as the adoption of minimally invasive surgical techniques, have boded well for market growth in the said historical period.

The glaucoma therapeutics market revenue will likely total US$ 6.6 Bn for 2021, according to Fact.MR. Overall, the market is expected to reach US$ 10 Bn by 2031, expanding 1.5x across the forthcoming decade. Demand for beta-blockers drug class will accelerate, anticipated to register a CAGR of 4.7% from 2021-2031.

Key Companies Profiled:

• Allergan Plc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Santen Pharmaceuticals Co. Ltd.
• Valeant Pharmaceuticals Inc.
• Aerie Pharmaceuticals Inc.

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Glaucoma Therapeutics market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Glaucoma Therapeutics

The report offers actionable and valuable market insights of Glaucoma Therapeutics. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Glaucoma Therapeutics Market across various industries and regions

Competitive Landscape

Strategic collaborations enable manufacturers to increase production and meet consumer demand which will increase revenue and market share. New products and technologies will enable end-users to benefit from products that are eco-friendly by nature. Key developments in the market are as follows:

• In May 2020, the U.S Food & Drug Administration approved Allergan Plc.’s DURYSTATM (bimatoprost implant) New Drug Application. The drug is amongst the first intracameral, sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma, or ocular hypertension
• In October 2021, Novartis AG pledged to work with partners all around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care. The company has partnered with the International Agency for the Prevention of Blindness during the World Sight Day to initiate the #LoveYourEyes campaign

Key Segments Covered

• Drug Class
  • Prostaglandins
  • Beta Blockers
  • Alpha Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Medications
  • Cholinergic Medications
• End User
  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

Key Questions Covered in the Glaucoma Therapeutics Market Report

• What is the projected value of the Glaucoma Therapeutics factors Industry in 2022?
• At what rate will the global Glaucoma Therapeutics factors market size grow until 2032?
• Which are the factors hampering the growth of Glaucoma Therapeutics factors?
• Which region is expected to lead in the global Glaucoma Therapeutics factors market By 2032?
• Which are the factors driving the Glaucoma Therapeutics factors Industry during the forecast period?
• What is the expected market value of the Glaucoma Therapeutics factors market during the forecast period?

Regional Analysis For Glaucoma Therapeutics Market:

• APAC (Japan, China, South Korea, Australia, India, and the rest of APAC; the rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (USA, Canada and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, United Arab Emirates, South Africa)

Share Your Requirements & Get Customized Reports:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4775?AS

Contact: 
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Email : sales@factmr.com